Citations (92)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Mohamed F. AlAjmi, Md Tabish Rehman & Afzal Hussain. (2022) Celecoxib, Glipizide, Lapatinib, and Sitagliptin as potential suspects of aggravating SARS-CoV-2 (COVID-19) infection: a computational approach. Journal of Biomolecular Structure and Dynamics 40:24, pages 13747-13758.
Read now
Read now
Prateek Pathak, Vladislav Naumovich, Maria Grishina & Vladimir Potemkin. (2022) The study of EGFR-ligand complex electron property relationship with biological activity. Journal of Biomolecular Structure and Dynamics 40:1, pages 375-388.
Read now
Read now
Ke-Ying Chen, Kai-Li Zhou, Yan-Yue Lou & Jie-Hua Shi. (2019) Exploring the binding interaction of calf thymus DNA with lapatinib, a tyrosine kinase inhibitor: multi-spectroscopic techniques combined with molecular docking. Journal of Biomolecular Structure and Dynamics 37:3, pages 576-583.
Read now
Read now
Suresh Kumar Muthuvel, Elakkiya Elumalai, Girija K.Hemalatha K.. (2018) Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor. Journal of Receptors and Signal Transduction 38:5-6, pages 475-483.
Read now
Read now
Nyam-Osor Chimge, Sara Ahmed-Alnassar & Baruch Frenkel. (2017) Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer. Cell Cycle 16:4, pages 312-318.
Read now
Read now
Ruohan Zhang, Hongyu Qiao, Suning Chen, Xu Chen, Kefeng Dou, Li Wei & Jian Zhang. (2016) Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biology & Therapy 17:9, pages 925-934.
Read now
Read now
Lauren V. Wood, Antonio Fojo, Brenda D. Roberson, Meghan S. B. Hughes, William Dahut, James L. Gulley, Ravi A. Madan, Philip M. Arlen, Marianna Sabatino, David F. Stroncek, Luciano Castiello, Jane B. Trepel, Min-Jung Lee, Howard L. Parnes, Seth M. Steinberg, Masaki Terabe, Julia Wilkerson, Ira Pastan & Jay A. Berzofsky. (2016) TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. OncoImmunology 5:8.
Read now
Read now
Ya-Bing Zheng, Yang Yu, Bo Chen, Jin-Lin Hu, Tian Jing & Xi-Ping Zhang. (2016) Inhibitor Response to HER2 G776YVMA In-frame Insertion in HER2-positive Breast Cancer. Cancer Investigation 34:3, pages 123-129.
Read now
Read now
Sarah Jacca, Valeria Rolih, Elena Quaglino, Valentina Franceschi, Giulia Tebaldi, Elisabetta Bolli, Alfonso Rosamilia, Simone Ottonello, Federica Cavallo & Gaetano Donofrio. (2016) Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. OncoImmunology 5:3.
Read now
Read now
Wei Liu, Jin-Feng Ning, Qing-Wei Meng, Jing Hu, Yan-Bin Zhao, Chao Liu & Li Cai. (2015) Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Drug Design, Development and Therapy 9, pages 3837-3851.
Read now
Read now
Gerald M Higa. (2009) Breast cancer: beyond the cutting edge. Expert Opinion on Pharmacotherapy 10:15, pages 2479-2498.
Read now
Read now
Articles from other publishers (81)
Pragya Dubey, Dharam Pal Pathak, Faraat Ali & Garima Chauhan. (2023) 1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating
Breast Cancer Cell Lines. Current Organic Chemistry 26:24, pages 2188-2202.
Crossref
Crossref
Motahareh Mortazavi, Masoomeh Eskandari, Fatemeh Moosavi, Tahereh Damghani, Mehdi Khoshneviszadeh, Somayeh Pirhadi, Luciano Saso, Najmeh Edraki & Omidreza Firuzi. (2023) Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties. Scientific Reports 13:1.
Crossref
Crossref
Hiram Coria-Rodríguez, Soledad Ochoa, Guillermo de Anda-Jáuregui & Enrique Hernández-Lemus. (2023) Drug repurposing for Basal breast cancer subpopulations using modular network signatures. Computational Biology and Chemistry 105, pages 107902.
Crossref
Crossref
Weidong Jiang, Ye Li, Jian-Quan Liu & Xiang-Shan Wang. (2023)
Copper-Catalyzed Consecutive Ullmann, Decarboxylation, Oxidation, and Dehydration Reaction for Synthesis of Pyrrolo or Pyrido[1,2-
a
]imidazo[1,2-
c
]quinazolines
. Organic Letters 25:27, pages 5123-5127.
Crossref
Crossref
Ligeri Papaioannou, Argiris Kolokithas-Ntoukas, Lito Karkaletsou, Stylianos Didaskalou, Maria D. Koffa & Konstantinos Avgoustakis. (2023) NIR-responsive, lapatinib-loaded gold nanorods for combined photothermal and pharmacological treatment of HER2 positive breast cancer: In vitro evaluation and cell studies. Journal of Drug Delivery Science and Technology 82, pages 104347.
Crossref
Crossref
Nidhi Singh, Kolimi Prashanth Reddy, Priyanka Das, Bhamare Kumudini Kishor & Pallab Datta. (2023) Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer. Journal of Drug Delivery Science and Technology 82, pages 104315.
Crossref
Crossref
Prateek Pathak, Santosh Gupta, Maria Grishina, Habibullah Khalilullah & Amita Verma. (2022) Design, synthesis, and in silico study of hybrid oxoazetidine conjugated thiazoles as anti‐EGFR with cytotoxicity activity. Journal of Biochemical and Molecular Toxicology 37:4.
Crossref
Crossref
Xinyi Wang, Gonghuan Tang, Hui Guo, Jingjing Ma, Dongmei Liu, Yuwei Wang, Ruyi Jin, Zhi Li & Yuping Tang. (2023) Research Progress on the Anti-Tumor Mechanism and Reversal of Multidrug Resistance of Zuojin Pill and its Main Components, Evodiamine and Berberine. Natural Product Communications 18:3, pages 1934578X2311614.
Crossref
Crossref
Charanjit Kaur, Bhargavi Sharma & Kunal Nepali. (2022) Switch Pocket Kinase: An Emerging Therapeutic Target for the Design of Anticancer
Agents. Anti-Cancer Agents in Medicinal Chemistry 22:15, pages 2662-2670.
Crossref
Crossref
Ziyin Tian, Yan Yang, He Wu, Yongye Chen, Hao Jia, Lei Zhu, Runjia He, Yibo Jin, Bei Zhou, Chunpo Ge, Yanxia Sun & Yun Yang. (2022) The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers. Heliyon 8:8, pages e10410.
Crossref
Crossref
Fabio Urbina, Christopher T. Lowden, J. Christopher Culberson & Sean Ekins. (2022) MegaSyn: Integrating Generative Molecular Design, Automated Analog Designer, and Synthetic Viability Prediction. ACS Omega 7:22, pages 18699-18713.
Crossref
Crossref
Parin Salim Sidat, Tasneem Mohamadbin Kasim Jaber, Shwetang Ramesh Vekariya, Azmin Mahervan Mogal, Aarifa Mustak Patel & Malleshappa Noolvi. (2022) Anticancer Biological Profile of Some Heterocylic Moieties-Thiadiazole, Benzimidazole, Quinazoline, and Pyrimidine. Pharmacophore 13:4, pages 59-71.
Crossref
Crossref
Tao Cao, Michael L. Martini, Kwang-Su Park, H. Ümit Kaniskan & Jian Jin. 2022. Comprehensive Heterocyclic Chemistry IV. Comprehensive Heterocyclic Chemistry IV
86
228
.
Xiaoxiao Zhang & Maik Kschischo. (2021) MFmap: A semi-supervised generative model matching cell lines to tumours and cancer subtypes. PLOS ONE 16:12, pages e0261183.
Crossref
Crossref
Leonie C. Naßwetter, Markus Fischer, Holger A. Scheidt & Heiko Heerklotz. (2021) Membrane-water partitioning – Tackling the challenges of poorly soluble drugs using chaotropic co-solvents. Biophysical Chemistry 277, pages 106654.
Crossref
Crossref
Zilai Wang, Norton P. Peet, Pin Zhang, Yuwei Jiang & Lijun Rong. (2021) Current Development of Glioblastoma Therapeutic Agents. Molecular Cancer Therapeutics 20:9, pages 1521-1532.
Crossref
Crossref
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park & Yeon-Sun Seong. (2021) Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals 14:6, pages 589.
Crossref
Crossref
Prateek Pathak, Hrvoje Rimac, Maria Grishina, Amita Verma & Vladimir Potemkin. (2020) Hybrid Quinazoline 1,3,5‐Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study. ChemMedChem 16:5, pages 822-838.
Crossref
Crossref
Shuai Wang, Xiao-Han Yuan, Sai-Qi Wang, Wen Zhao, Xiao-Bing Chen & Bin Yu. (2021) FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. European Journal of Medicinal Chemistry 214, pages 113218.
Crossref
Crossref
Guillermo García-Lainez, Ignacio Vayá, M. Pilar Marín, Miguel A. Miranda & Inmaculada Andreu. (2020) In vitro assessment of the photo(geno)toxicity associated with Lapatinib, a Tyrosine Kinase inhibitor. Archives of Toxicology 95:1, pages 169-178.
Crossref
Crossref
Yong Ling, Ji Liu, Jianqiang Qian, Chi Meng, Jing Guo, Weijie Gao, Biao Xiong, Changchun Ling & Yanan Zhang. (2020) Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy. Current Medicinal Chemistry 27:42, pages 7264-7288.
Crossref
Crossref
Hany W. Darwish, Ahmed H. Bakheit, Nasser S. Al-shakliah, A. F. M. Motiur Rahman & Ibrahim A. Darwish. (2020) Experimental and computational evaluation of kolliphor RH 40 as a new fluorescence enhancer in development of a micellar-based spectrofluorimetric method for determination of lapatinib in tablets and urine. PLOS ONE 15:12, pages e0239918.
Crossref
Crossref
Xueli Li, Kongzhen Hu, Wenfeng Liu, Yuanfeng Wei, Runhua Sha, Yongxuan Long, Yanjiang Han, Penhui Sun, Hubing Wu, Guiping Li, Ganghua Tang & Shun Huang. (2020) Synthesis and evaluation of [18F]FP-Lys-GE11 as a new radiolabeled peptide probe for epidermal growth factor receptor (EGFR) imaging. Nuclear Medicine and Biology 90-91, pages 84-92.
Crossref
Crossref
Ivan Haralampiev, Diego Javier Alonso de Armiño, Meike Luck, Markus Fischer, Tobias Abel, Daniel Huster, Santiago Di Lella, Holger A. Scheidt & Peter Müller. (2020) Interaction of the small-molecule kinase inhibitors tofacitinib and lapatinib with membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1862:11, pages 183414.
Crossref
Crossref
Ting Yu, Wei Bai, Yongfeng Su, Yaqi Wang, Meijian Wang & Chunhua Ling. (2020) Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis. Experimental and Molecular Pathology 116, pages 104484.
Crossref
Crossref
Jawad Fares, Deepak Kanojia, Aida Rashidi, Ilya Ulasov & Maciej S. Lesniak. (2020) Landscape of combination therapy trials in breast cancer brain metastasis. International Journal of Cancer 147:7, pages 1939-1952.
Crossref
Crossref
Debasis Das & Jian Hong. (2020) Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. Current Enzyme Inhibition 16:1, pages 4-19.
Crossref
Crossref
Vakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Ching-Yu Wang, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio & Gilberto de Lima Lopes. (2020) A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. The Breast 49, pages 141-148.
Crossref
Crossref
H. G. Bheemanna, M. N. Manjunatha, K. S. Mamatha & V. Gayathri. Studies on ruthenium and rhodium complexes containing 6-pyridyl-5,6-dihydrobenzo[4,5]-imidazo[1,2-c]quinazoline and catalytic transfer hydrogenation. Studies on ruthenium and rhodium complexes containing 6-pyridyl-5,6-dihydrobenzo[4,5]-imidazo[1,2-c]quinazoline and catalytic transfer hydrogenation.
Binayak Kumar, Deepu Sharma, Jyotsna Gorantala & Sri Krishna Jayadev Magani. 2020. Novel therapeutic approaches for gastrointestinal malignancies. Novel therapeutic approaches for gastrointestinal malignancies
43
57
.
Efthymios-Spyridon Gavriil, Aris Doukatas, Theodoros Karampelas, Vassilios Myrianthopoulos, Spyridon Dimitrakis, Emmanuel Mikros, Panagiotis Marakos, Constantin Tamvakopoulos & Nicole Pouli. (2019) Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy. European Journal of Medicinal Chemistry 176, pages 393-409.
Crossref
Crossref
Richard Schroeder, Mary Sfondouris, Navneet Goyal, Rajesh Komati, Achira Weerathunga, Cory Gettridge, Cheryl L. Klein Stevens, Frank E. Jones & Jayalakshmi Sridhar. (2019) Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines. ACS Omega 4:6, pages 10610-10619.
Crossref
Crossref
Mohammed M. Alanazi, Hamad M. Alkahtani, Abdulrahman A. Almehizia, Mohamed W. Attwa, Ahmed H. Bakheit & Hany W. Darwish. (2019) Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation. RSC Advances 9:34, pages 19325-19332.
Crossref
Crossref
Debasis Das & Jian Hong. (2019) Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. European Journal of Medicinal Chemistry 170, pages 55-72.
Crossref
Crossref
Wenxiang Wang, Yuxia Gao, Jing Hai, Jing Yang & Shufeng Duan. (2019) HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way. Bioscience Reports 39:3.
Crossref
Crossref
Clinton G. L. Veale. (2019) Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease. ChemMedChem 14:4, pages 386-453.
Crossref
Crossref
Anna Maria Barbuti, Guan-Nan Zhang, Pranav Gupta, Silpa Narayanan & Zhe-Sheng Chen. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
1
11
.
Shayna Stein, Rui Zhao, Hiroshi Haeno, Igor Vivanco & Franziska Michor. (2018) Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLOS Computational Biology 14:1, pages e1005924.
Crossref
Crossref
Liuchang Wang, Pengna Li, Baolin Li, Yawen Wang, Jiangtao Li & Limei Song. (2017) Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives. Molecules 22:10, pages 1624.
Crossref
Crossref
Russell Burcombe. (2017) Current treatment of HER 2+ metastatic breast cancer. British Journal of Nursing 26:Sup16a, pages S7-S14.
Crossref
Crossref
Claire Ryan. (2017) Introduction. British Journal of Nursing 26:Sup16a, pages S4-S6.
Crossref
Crossref
Claire Ryan, Russell Burcombe & Tracey Coleby. (2017) Foreword. British Journal of Nursing 26:Sup16a, pages S3-S3.
Crossref
Crossref
Claire Ryan. (2017) Improving patient care: expert nursing and service development. British Journal of Nursing 26:Sup16a, pages S21-S25.
Crossref
Crossref
Tracey Coleby. (2017) Defining what matters most to patients. British Journal of Nursing 26:Sup16a, pages S15-S20.
Crossref
Crossref
Aurelio Moya-García, Tolulope Adeyelu, Felix A. Kruger, Natalie L. Dawson, Jon G. Lees, John P. Overington, Christine Orengo & Juan A. G. Ranea. (2017) Structural and Functional View of Polypharmacology. Scientific Reports 7:1.
Crossref
Crossref
Terry W. Moody, Irene Ramos-Alvarez, Paula Moreno, Samuel A. Mantey, Lisa Ridnour, David Wink & Robert T. Jensen. (2017) Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides 90, pages 90-99.
Crossref
Crossref
Gergő Tóth, Ádám Jánoska, Gergely Völgyi, Zoltán-István Szabó, Gábor Orgován, Arash Mirzahosseini & Béla Noszál. (2017) Physicochemical Characterization and Cyclodextrin Complexation of the Anticancer Drug Lapatinib. Journal of Chemistry 2017, pages 1-9.
Crossref
Crossref
Ningning Gao, Jingjing Zhong, Xiaodong Wang, Zhenchao Jin, Wang Li, Yu Liu, Yuwen Diao, Zhulin Wang, Wenqi Jiang & Guangyi Jin. (2016) Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific Reports 6:1.
Crossref
Crossref
Huiping Shi, Weili Zhang, Qiaoming Zhi & Min Jiang. (2016) Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. Tumor Biology 37:12, pages 15411-15431.
Crossref
Crossref
Ying Hong Li, Pan Pan Wang, Xiao Xu Li, Chun Yan Yu, Hong Yang, Jin Zhou, Wei Wei Xue, Jun Tan & Feng Zhu. (2016) The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective. PLOS ONE 11:11, pages e0165737.
Crossref
Crossref
Md. Zahirul Kabir, Abdul Kadir Mukarram, Saharuddin B. Mohamad, Zazali Alias & Saad Tayyab. (2016) Characterization of the binding of an anticancer drug, lapatinib to human serum albumin. Journal of Photochemistry and Photobiology B: Biology 160, pages 229-239.
Crossref
Crossref
YANG CAI, XIANG YAN, GUOQING ZHANG, WEIHONG ZHAO & SHUNCHANG JIAO. (2016) MicroRNA-205 increases the sensitivity of docetaxel in breast cancer. Oncology Letters 11:2, pages 1105-1109.
Crossref
Crossref
Suning Chen, Xingmei Zhu, Hongyu Qiao, Mingxiang Ye, Xiaofeng Lai, Shentong Yu, Likun Ding, Aidong Wen & Jian Zhang. (2015) Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib. Tumor Biology 37:2, pages 2321-2331.
Crossref
Crossref
Xuli Meng, Yongfeng Li, Hongchao Tang, Weimin Mao, Hongjian Yang, Xiaojia Wang, Xianfeng Ding & Shangnao Xie. (2015) Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino Acids 48:2, pages 487-497.
Crossref
Crossref
Xiang-Xiang Tao, Yong-Tao Duan, Long-Wang Chen, Dan-Jie Tang, Meng-Ru Yang, Peng-Fei Wang, Chen Xu & Hai-Liang Zhu. (2016) Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 26:2, pages 677-683.
Crossref
Crossref
AKM Azad, Alfons Lawen & Jonathan M Keith. (2015) Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling. BMC Systems Biology 9:1.
Crossref
Crossref
Zhe Li, Sheng‐Sheng Yang, Pei‐Hao Yin, Tao Chang, Lin‐Xiang Shi, Lin Fang & Guo‐En Fang. (2015) Activated estrogen receptor‐mitogen‐activated protein kinases cross talk confer acquired resistance to lapatinib. Thoracic Cancer 6:6, pages 695-703.
Crossref
Crossref
Carlos Acevedo-Gadea, Christos Hatzis, Gina Chung, Neal Fishbach, Kimberly Lezon-Geyda, Daniel Zelterman, Michael P. DiGiovanna, Lyndsay Harris & Maysa M. Abu-Khalaf. (2015) Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Research and Treatment 150:1, pages 157-167.
Crossref
Crossref
Demet Candas, Chung-Ling Lu, Ming Fan, Frank Y.S. Chuang, Colleen Sweeney, Alexander D. Borowsky & Jian Jian Li. (2014) Mitochondrial MKP1 Is a Target for Therapy-Resistant HER2-Positive Breast Cancer Cells. Cancer Research 74:24, pages 7498-7509.
Crossref
Crossref
Bandana Chakravarti, Tahseen Akhtar, Byanju Rai, Manisha Yadav, Jawed Akhtar Siddiqui, Shailendra Kumar Dhar Dwivedi, Ravi Thakur, Anup Kumar Singh, Abhishek Kumar Singh, Harish Kumar, Kainat Khan, Subhashis Pal, Srikanta Kumar Rath, Jawahar Lal, Rituraj Konwar, Arun Kumar Trivedi, Dipak Datta, Durga Prasad Mishra, Madan Madhav Godbole, Sabyasachi Sanyal, Naibedya Chattopadhyay & Atul Kumar. (2014) Thioaryl Naphthylmethanone Oxime Ether Analogs as Novel Anticancer Agents. Journal of Medicinal Chemistry 57:19, pages 8010-8025.
Crossref
Crossref
Byeonghwa Song, Hyung Jung Yoo, Eun-Goo Jeong, Sung Jae Kim, Jong Mo Seo, Tae-You Kim & Dong-Il Cho. (2014) Fabrication of biodegradable polymeric micro chambers encapsulated with pulverized drug for bacteria-based microrobots. Fabrication of biodegradable polymeric micro chambers encapsulated with pulverized drug for bacteria-based microrobots.
Saurabh Prabhu, Frederick Harris, Robert Lea & Timothy J. Snape. (2014) Small-molecule clinical trial candidates for the treatment of glioma. Drug Discovery Today 19:9, pages 1298-1308.
Crossref
Crossref
Amr Mohamed, Bassel El-Rayes, Fadlo R. Khuri & Nabil F. Saba. (2014) Targeted therapies in metastatic esophageal cancer: Advances over the past decade. Critical Reviews in Oncology/Hematology 91:2, pages 186-196.
Crossref
Crossref
Jayalakshmi Sridhar, Mary E. Sfondouris, Melyssa R. Bratton, Thuy-Linh K. Nguyen, Ian Townley, Cheryl L. Klein Stevens & Frank E. Jones. (2014) Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer. Bioorganic & Medicinal Chemistry Letters 24:1, pages 126-131.
Crossref
Crossref
Dramane Lainé, Matthew Lucas, Francisco Lopez‐Tapia & Stephen Lynch. 2013. Medicinal Chemistry Approaches to Personalized Medicine. Medicinal Chemistry Approaches to Personalized Medicine
255
288
.
Yong Yook Lee, Hwang-Phill Kim, Min Jueng Kang, Byoung-Kyu Cho, Sae-Won Han, Tae-You Kim & Eugene C Yi. (2013) Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Experimental & Molecular Medicine 45:11, pages e64-e64.
Crossref
Crossref
Dong-Dong Li, Ya-Juan Qin, Jian Sun, Jing-Ran Li, Fei Fang, Qian-Ru Du, Yong Qian, Hai-Bin Gong & Hai-Liang Zhu. (2013) Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors. PLoS ONE 8:8, pages e69427.
Crossref
Crossref
Lorenzo Palmieri & Giulio Rastelli. (2013) αC helix displacement as a general approach for allosteric modulation of protein kinases. Drug Discovery Today 18:7-8, pages 407-414.
Crossref
Crossref
Andy Barker & David Andrews. 2013. Introduction to Biological and Small Molecule Drug Research and Development. Introduction to Biological and Small Molecule Drug Research and Development
255
281
.
Dana Faingold, Dawn Russell-Hermanns & Silvin Bakalian. 2013. Experimental and Clinical Metastasis. Experimental and Clinical Metastasis
403
444
.
Catalin Mihalcioiu. 2013. Experimental and Clinical Metastasis. Experimental and Clinical Metastasis
299
318
.
Suneet Shukla, Zhe-Sheng Chen & Suresh V. Ambudkar. (2012) Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates 15:1-2, pages 70-80.
Crossref
Crossref
Walid Shaib, Scott Kono & Nabil Saba. (2012) Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck. Journal of Oncology 2012, pages 1-11.
Crossref
Crossref
Vivian Wai Yan Lui, Cecilia Pik Yuk Lau, KaKiu Ho, Margaret Heung Ling Ng, Suk Hang Cheng, Sai-Wah Tsao, Chi Man Tsang, Kenny Ieng Kit Lei, Anthony TC Chan & Tony Shu Kam Mok. (2010) Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Investigational New Drugs 29:6, pages 1241-1252.
Crossref
Crossref
Adriana Albini, Eugenio Cesana, Francesco Donatelli, Rosaria Cammarota, Eraldo O Bucci, Massimo Baravelli, Claudio Anzà & Douglas M Noonan. (2011) Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiology 7:5, pages 693-704.
Crossref
Crossref
Kamelia M. Amin, Hanan H. Georgey & Fadi M. Awadallah. (2010) EGFR tyrosine kinase targeted compounds: synthesis, docking study, and in vitro antitumor activity of some new quinazoline and benzo[d]isothiazole derivatives. Medicinal Chemistry Research 20:7, pages 1042-1053.
Crossref
Crossref
David E. Misek & Evelyn H. Kim. (2011) Protein Biomarkers for the Early Detection of Breast Cancer. International Journal of Proteomics 2011, pages 1-9.
Crossref
Crossref
Kathleen Aertgeerts, Robert Skene, Jason Yano, Bi-Ching Sang, Hua Zou, Gyorgy Snell, Andy Jennings, Keiji Iwamoto, Noriyuki Habuka, Aki Hirokawa, Tomoyasu Ishikawa, Toshimasa Tanaka, Hiroshi Miki, Yoshikazu Ohta & Satoshi Sogabe. (2011) Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein. Journal of Biological Chemistry 286:21, pages 18756-18765.
Crossref
Crossref
Jason G. Kettle & Richard A. Ward. (2010) Toward the Comprehensive Systematic Enumeration and Synthesis of Novel Kinase Inhibitors Based on a 4-Anilinoquinazoline Binding Mode. Journal of Chemical Information and Modeling 50:4, pages 525-533.
Crossref
Crossref
Julian R. Molina, Scott H. Kaufmann, Joel M. Reid, Stephen D. Rubin, Marina Gálvez-Peralta, Robert Friedman, Karen S. Flatten, Kevin M. Koch, Tona M. Gilmer, Robert J. Mullin, Roxanne C. Jewell, Sara J. Felten, Sumithra Mandrekar, Alex A. Adjei & Charles Erlichman. (2008) Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research 14:23, pages 7900-7908.
Crossref
Crossref
Chun-ling Dai, Amit K. Tiwari, Chung-Pu Wu, Xiao-dong Su, Si-Rong Wang, Dong-geng Liu, Charles R. AshbyJr.Jr., Yan Huang, Robert W. Robey, Yong-ju Liang, Li-ming Chen, Cheng-Jun Shi, Suresh V. Ambudkar, Zhe-Sheng Chen & Li-wu Fu. (2008) Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research 68:19, pages 7905-7914.
Crossref
Crossref